Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q
Tweet Send to a Friend
Stifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.Analyst Annabel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
